Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) are specialized treatment approaches used for selected cancers involving the peritoneal cavity. Cytoreductive surgery aims to remove visible tumour deposits, while HIPEC involves delivering heated chemotherapy directly into the abdominal cavity during surgery.
Cytoreductive surgery, also called debulking surgery or cytoreduction, is performed to remove as much visible cancer as safely possible from the abdominal and pelvic cavity.
Peritoneal cancers can spread across the surfaces of abdominal organs, making surgery more complex than removing a single localized tumour. During cytoreductive surgery, the surgeon evaluates the abdominal cavity and removes visible tumour deposits from affected areas when this can be achieved safely.
For selected ovarian and peritoneal cancers, achieving complete or near-complete cytoreduction can be an important part of treatment planning.
HIPEC stands for Hyperthermic Intraperitoneal Chemotherapy. After cytoreductive surgery, heated chemotherapy may be circulated directly inside the abdominal cavity using a specialized technique. The goal is to expose remaining microscopic cancer cells on peritoneal surfaces to chemotherapy at the time of surgery.
Unlike conventional intravenous chemotherapy, HIPEC delivers chemotherapy directly into the peritoneal cavity. The procedure is performed in a controlled operating-room setting and requires specialized surgical, anesthesia, and critical-care support.
Cytoreductive Surgery and HIPEC generally involve several important stages, from detailed cancer evaluation and tumour removal to heated chemotherapy and postoperative monitoring. The treatment plan is individualized according to the type and extent of cancer, previous treatment, and overall health.
Before surgery, the medical team evaluates imaging, pathology reports, previous treatment, overall health, and the extent of cancer spread to determine whether CRS-HIPEC may be appropriate.
The surgeon removes visible tumour deposits from the abdominal and pelvic cavity as safely and completely as possible, depending on the extent of disease.
Once visible tumour has been removed, heated chemotherapy is circulated inside the abdominal cavity according to the planned treatment protocol.
After the chemotherapy circulation is completed, the abdominal cavity is cleared and the surgical procedure is completed according to the operative plan.
Because CRS-HIPEC is an extensive procedure, patients require careful postoperative monitoring, recovery planning, and appropriate follow-up during the recovery period.
The exact CRS-HIPEC approach varies between patients. Treatment decisions depend on the cancer type, stage, distribution of peritoneal disease, response to previous treatment, overall health, and whether the visible disease can be safely removed. A multidisciplinary team may assess these factors before recommending treatment.
Cytoreductive surgery may be considered for selected patients with cancers involving the peritoneal cavity. Careful evaluation is required to determine whether the visible disease can be safely removed and whether the potential benefits of surgery outweigh the possible risks.
Cytoreductive surgery may be considered when cancer has spread within the peritoneal cavity and the pattern of disease may be suitable for surgical treatment.
The medical team assesses whether the visible disease can potentially be removed safely and whether meaningful cytoreduction can be achieved without unacceptable surgical risk.
The patient's overall health, physical condition, organ function, and ability to tolerate major surgery are important considerations before CRS-HIPEC is planned.
When previous treatment has been given, the cancer's response to therapy may be reviewed as part of the assessment for cytoreductive surgery.
A multidisciplinary cancer team reviews the patient's disease and treatment options to determine whether meaningful cytoreduction can potentially be achieved.
The expected benefits of surgery are weighed against the potential risks and recovery requirements before CRS-HIPEC is recommended.
Patient selection is an important part of CRS-HIPEC planning because this is a major surgical procedure. A detailed evaluation helps the treatment team determine whether cytoreductive surgery, with or without HIPEC, is appropriate for the individual patient's cancer and overall condition.
HIPEC is not a routine treatment for every abdominal or gynecological cancer. Eligibility depends on the type and stage of cancer, extent of peritoneal disease, response to previous treatment, overall health, and whether meaningful cytoreduction can potentially be achieved.
The type and origin of cancer are considered to determine whether CRS-HIPEC may be an appropriate treatment option.
The cancer stage helps the treatment team understand the extent of disease and assess whether HIPEC may be suitable.
The location and distribution of tumour deposits within the abdominal and pelvic cavity are evaluated before treatment.
The amount and extent of cancer involving the peritoneal surfaces are important factors in assessing the feasibility of cytoreductive surgery.
When chemotherapy has already been given, the cancer's response to treatment may be considered when evaluating HIPEC.
The medical team assesses whether complete or optimal cytoreduction may potentially be achieved safely during surgery.
General health, physical condition, and fitness for major surgery are evaluated before CRS-HIPEC is considered.
Previous surgery, chemotherapy, radiation therapy, or other cancer treatments may influence the treatment decision.
Individual treatment goals and the expected benefits and risks of CRS-HIPEC are considered as part of the overall treatment plan.
For some ovarian and fallopian tube cancers, guidelines and clinical evidence support considering HIPEC in selected treatment settings, while evidence remains limited or evolving for other situations. A specialist multidisciplinary team can assess the individual patient's cancer and overall condition before recommending CRS-HIPEC.
Because CRS-HIPEC is an extensive procedure, it can involve significant risks and requires careful patient selection. The potential complications and individual risks should be evaluated before treatment by the surgical and oncology team.
Infection can occur after major abdominal surgery and may require additional monitoring or treatment.
Extensive cytoreductive surgery may carry a risk of bleeding during or after the procedure.
Major surgery and reduced mobility during recovery can increase the risk of blood clots.
Depending on the extent of surgery, bowel or other digestive complications may occur and require appropriate management.
Changes in fluid balance and electrolyte levels may occur during or after extensive surgery and require monitoring.
CRS-HIPEC is a major procedure, and recovery may take time with careful postoperative monitoring and supportive care.
Depending on the organs and tissues involved in surgery, complications affecting organ function may occur.
HIPEC involves heated chemotherapy, which may cause treatment-related effects that require appropriate monitoring.
Prolonged anesthesia and extensive surgery can involve additional risks that are assessed as part of preoperative planning.
The potential benefits and risks of CRS-HIPEC should be discussed in detail with the treating surgical and oncology team before treatment. Individual risk can vary according to the cancer type, extent of disease, overall health, previous treatments, and complexity of surgery.
Find answers to common questions about cytoreductive surgery, HIPEC, patient selection, ovarian and fallopian tube cancer treatment, and recovery.
© 2026 Dr. Swasti All Rights Reserved. Designed by Innovative Digital Marketing